Focused On-demand Library for Serine--tRNA ligase, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NP81

UPID:

SYSM_HUMAN

Alternative names:

SerRSmt; Seryl-tRNA synthetase; Seryl-tRNA(Ser/Sec) synthetase

Alternative UPACC:

Q9NP81; A6NHW7; B4DE10; Q9BVP3

Background:

Serine--tRNA ligase, mitochondrial (SerRSmt), also known as Seryl-tRNA synthetase, plays a crucial role in protein synthesis by catalyzing the attachment of serine to tRNA(Ser). This enzyme is pivotal in the translation process, ensuring the accurate production of proteins by cells. Its ability to also aminoacylate tRNA(Sec) with serine, forming misacylated tRNA L-seryl-tRNA(Sec), is essential for the further conversion into selenocysteinyl-tRNA(Sec), highlighting its multifaceted role in biological systems.

Therapeutic significance:

SerRSmt is implicated in Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome, a multisystem disorder with severe outcomes. Understanding the role of Serine--tRNA ligase, mitochondrial could open doors to potential therapeutic strategies, offering hope for targeted treatments for affected individuals.